Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Pancreatic Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Parathyroid Neoplasms 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Lung Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 7Carboplatin 7durvalumab 5Ipilimumab 5aldesleukin 4Paclitaxel 4Irinotecan 4Gemcitabine 4Docetaxel 4Cisplatin 4sargramostim 3atezolizumab 3Topotecan 3Polymerase Chain Reaction 3Magnetic Resonance Spectroscopy 3temsirolimus 2talazoparib 2carfilzomib 2cabozantinib 2budigalimab 2Trastuzumab 2Therapeutics 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Injections 2Gene Expression Profiling 2Fulvestrant 2Fluorodeoxyglucose F18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Interleukin-12 × Gynecologic × Clear all
NCT00028535 2013-06-04

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
18 enrolled
BreastGastrointestinalGynecologicThoracic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡